Clearview Cancer Institute: Company Profile
Background
Overview
Clearview Cancer Institute (CCI) is a leading cancer treatment facility based in Huntsville, Alabama, specializing in comprehensive outpatient care for patients diagnosed with cancer and blood disorders. Established in 1985, CCI has been dedicated to providing innovative treatments and compassionate care for over 40 years.
Mission and Vision
CCI's mission is to deliver high-quality, innovative, and compassionate patient care, leveraging advanced technology and a dedicated team to achieve optimal outcomes. The institute envisions being a regional leader in cancer care, offering accessible and personalized treatment options to the communities it serves.
Primary Area of Focus
The institute focuses on medical oncology and hematology, providing services such as chemotherapy, radiation therapy, diagnostic imaging, genetic testing, and participation in clinical trials. Its commitment to research and involvement in Phase I-IV clinical trials offers patients access to potentially life-saving therapies.
Industry Significance
As one of the largest community oncology practices in Alabama, CCI plays a pivotal role in delivering specialized cancer care to the region. Its longstanding presence and comprehensive services make it a cornerstone in the fight against cancer in North Alabama.
Key Strategic Focus
Core Objectives
- Comprehensive Care: Provide a full spectrum of cancer care services, including prevention, diagnosis, treatment, and survivorship programs.
- Patient-Centered Approach: Ensure personalized treatment plans tailored to individual patient needs, emphasizing compassionate care.
- Community Engagement: Maintain a strong presence in local communities through education, support groups, and outreach programs.
Specific Areas of Specialization
- Medical Oncology and Hematology: Expertise in diagnosing and treating various cancers and blood disorders.
- Clinical Research: Active participation in clinical trials, offering patients access to cutting-edge therapies.
- Genetic Testing and Counseling: Providing genetic assessments to inform personalized treatment strategies.
Key Technologies Utilized
- Advanced Radiation Therapy: Utilization of technologies such as TrueBeam, Halcyon, and Bravos for precise treatment delivery.
- Diagnostic Imaging: Comprehensive imaging services, including Ultrasound, CT, MRI, and PET-CT scans.
- In-House Laboratory Services: On-site laboratories for timely and accurate diagnostic results.
Primary Markets Targeted
CCI primarily serves the North Alabama region, with multiple locations in cities such as Huntsville, Decatur, Florence, Oxford, Jasper, Cullman, and Scottsboro. Its services are accessible to a diverse patient population across these communities.
Financials and Funding
Estimated Revenue
CCI's estimated annual revenue is approximately $71 million, with an estimated revenue per employee of $318,309.
Funding History
As a private, physician-owned practice, CCI has not publicly disclosed specific funding rounds or investors. Its financial growth is attributed to its longstanding reputation and the expansion of services to meet community needs.
Utilization of Capital
Capital is primarily allocated towards enhancing patient care facilities, investing in advanced medical technologies, expanding research capabilities, and supporting community outreach programs.
Pipeline Development
Clinical Trials
CCI is actively involved in clinical research, participating in Phase I-IV clinical trials. This involvement provides patients with access to new and potentially life-saving treatments. The institute collaborates with leading cancer centers, including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, The Mayo Clinic Cancer Center, and others.
Research Initiatives
The institute focuses on areas such as targeted therapies, better detection methods, genomic testing, and personalized medicine. Its commitment to research is recognized by the Cancer Accreditation Program of the American College of Surgeons, which continues to award CCI Research their highest accommodation for clinical trial enrollment.
Technological Platform and Innovation
Proprietary Technologies
While specific proprietary technologies are not detailed, CCI employs advanced radiation therapy technologies and comprehensive diagnostic imaging services to enhance treatment precision and patient outcomes.
Significant Scientific Methods
- Clinical Trials: Engagement in various phases of clinical trials to evaluate new treatments and therapies.
- Genomic Testing: Utilization of genetic assessments to inform personalized treatment strategies.
- Advanced Imaging: Use of state-of-the-art imaging technologies for accurate diagnosis and treatment planning.
Leadership Team
Key Executives
- Andrew Bailey: Chief Information Officer (CIO)
- Nicholas Sharp: Chief Financial Officer (CFO)
- Michelle Brown: Chief Operations Officer (COO)
- Jennifer Smith: Imaging Director
- Bobbi Wilson: Director of Human Resources
- Andrea McCutcheon: Director of Front Office
- Cyndi Lemery: Director of Patient Programs
- Jonathan Ogden: Director of Pharmacy Operations
- Lisa Chapuran: Clinical Research Manager, Clinical Lead
- Mariam Parizad: Clinical Research Nurse
Professional Backgrounds and Contributions
The leadership team comprises professionals with extensive experience in healthcare management, operations, imaging, human resources, patient programs, pharmacy operations, and clinical research. Their collective expertise ensures the efficient and compassionate delivery of cancer care services.
Competitor Profile
Market Insights and Dynamics
The oncology care market in North Alabama is characterized by a growing demand for specialized cancer treatment.
